Abdulmohsen M. Alruwetei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abdulmohsen M. Alruwetei has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Masood Alam Khan
Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia
4 shared publications - Arif Khan
Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia
3 shared publications - Khaled S. Allemailem
Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia
3 shared publications - Raed A. Alharbi
Laboratory Medicine Department, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha 65779, Saudi Arabia
3 shared publications - Ahmad Almatroudi
Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia
2 shared publications - Fahad Abdulrahman Alhumaydhi
Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1471
Cracking ERα Y537S Resistance: Explainable Machine Learning-Guided Discovery and Molecular Dynamics Validation of Stable Candidate Ligands
Background/Objectives: Endocrine resistance due to activating mutations in the estrogen receptor alpha (ERα), especially Y537S, is still a big challenge in the treatment of hormone receptor-positive breast cancer, and there is a need to develop new small-molecule inhibitors that can overcome ligand-independent receptor activation. We used an integrated machine learning and molecular dynamics (MD)-based virtual screening (VS) approach to identify potential computationally prioritized hits of ERα Y537S in this study. Methods: The dataset (~3353 compounds) was characterized using molecular fingerprints and graphically represented by PCA and t-SNE to show structurally different clusters linked to potency (pIC50). To guarantee robust downstream model training, the diagnosis of structural and influential outliers was completed through the application of rigorous data quality control methods, including the Williams plot, Mahalanobis distance, and Cook’s distance diagnostics. This was followed by multiple benchmarks of machine learning classifiers (random forest, SVM, KNN, and CNN) for activity classification, yielding the highest AUC of 0.95 for the random forest classifier. Interpretable structure–activity insights were gained by the identification of key substructures of the fingerprint by SHAP and feature importance analysis that influence the predicted potency. Three lead candidates (Hit-1, Hit-2, and Hit-3) were screened and tested with a 200 ns all-atom MD simulation in comparison with a reference control to evaluate the binding stability. Comprehensive trajectory analysis, such as PCA, FEL, RDF, salt bridges, and DCCM, was completed following the structure-based identification of the most stable ligands. Results: Three candidates were identified as Hit-1, Hit-2, and Hit-3. Hit-3 was found to be bound in the most stable binding pose and had the most similar conformational behavior to the control, whereas Hit-2 showed transient pose instability associated with increased anti-correlated domain-level motions and an alternate high-salt-bridge conformational state. As no computational metric can be an absolute measure of experimental affinity, Hit-1 has the most favorable calculated end-point binding-energy estimate, while Hit-3 showed conformational stability in MD simulations. Conclusions: The computationally prioritized candidates can be subjected to further experimental testing, as the conducted docking, MD simulations, and end-point free energy analyses cannot establish overall compound binding, cell-based activity, pharmacological mechanism, or therapeutic efficacy.
- 16 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1471
Open AccessCracking ERα Y537S Resistance: Explainable Machine Learning-Guided Discovery and Molecular Dynamics Validation of Stable Candidate Ligands
Background/Objectives: Endocrine resistance due to activating mutations in the estrogen receptor alpha (ERα), especially Y537S, is still a big challenge in the treatment of hormone receptor-positive breast cancer, and there is a need to develop new small-molecule inhibitors that can overcome ligand-independent receptor activation. We used an integrated machine learning and molecular dynamics (MD)-based virtual screening (VS) approach to identify potential computationally prioritized hits of ERα Y537S in this study. Methods: The dataset (~3353 compounds) was characterized using molecular fingerprints and graphically represented by PCA and t-SNE to show structurally different clusters linked to potency (pIC50). To guarantee robust downstream model training, the diagnosis of structural and influential outliers was completed through the application of rigorous data quality control methods, including the Williams plot, Mahalanobis distance, and Cook’s distance diagnostics. This was followed by multiple benchmarks of machine learning classifiers (random forest, SVM, KNN, and CNN) for activity classification, yielding the highest AUC of 0.95 for the random forest classifier. Interpretable structure–activity insights were gained by the identification of key substructures of the fingerprint by SHAP and feature importance analysis that influence the predicted potency. Three lead candidates (Hit-1, Hit-2, and Hit-3) were screened and tested with a 200 ns all-atom MD simulation in comparison with a reference control to evaluate the binding stability. Comprehensive trajectory analysis, such as PCA, FEL, RDF, salt bridges, and DCCM, was completed following the structure-based identification of the most stable ligands. Results: Three candidates were identified as Hit-1, Hit-2, and Hit-3. Hit-3 was found to be bound in the most stable binding pose and had the most similar conformational behavior to the control, whereas Hit-2 showed transient pose instability associated with increased anti-correlated domain-level motions and an alternate high-salt-bridge conformational state. As no computational metric can be an absolute measure of experimental affinity, Hit-1 has the most favorable calculated end-point binding-energy estimate, while Hit-3 showed conformational stability in MD simulations. Conclusions: The computationally prioritized candidates can be subjected to further experimental testing, as the conducted docking, MD simulations, and end-point free energy analyses cannot establish overall compound binding, cell-based activity, pharmacological mechanism, or therapeutic efficacy.
- Open Access
- 20 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4580
Multi-Compartment Transcriptomics Identifies a Persistent Inflammatory Program and a Network-Derived Diagnostic Signature in Polycythemia Vera
Polycythemia vera (PV) is a JAK2V617F-driven myeloproliferative neoplasm characterized by erythroid expansion, increased thrombotic risk, and heterogeneous clinical outcomes. Although prior studies have described key transcriptional abnormalities—including Janus kinase–signal transducer and activator of transcription (JAK–STAT) hyperactivation and chronic myeloinflammation—most have examined single hematopoietic compartments. A multi-compartment approach may reveal conserved and lineage-specific disease-associated transcriptional programs. Here, an integrated, multi-compartment transcriptomic analysis of publicly available microarray datasets was performed, spanning bone marrow (BM) CD34+ progenitors, peripheral blood (PB) CD34+ progenitors, and whole blood from PV patients and healthy controls, with independent validation in neutrophils. Differential gene expression, pathway enrichment, and protein–protein interaction network analyses were used to delineate conserved versus compartment-specific transcriptional programs and to evaluate persistence of progenitor-derived signatures into mature myeloid cells. Across compartments, PV demonstrated consistent enrichment of inflammatory, interferon, and JAK–STAT-associated pathways despite limited overlap at the individual gene level, indicating that core disease processes are maintained through lineage- and differentiation-stage-specific transcriptional reprogramming. Network analysis identified highly connected hub genes, which were used to derive a single-sample gene set enrichment (ssGSEA) signature. This signature showed strong diagnostic performance across cohorts; remained enriched in PV neutrophils; and correlated with platelet count, indolent disease status, and reduced levels in post-splenectomy patients. Together, these findings support a model in which PV is driven by stable, progenitor-derived inflammatory programs that persist across myeloid differentiation while incorporating compartment-specific adaptations, and highlight the value of multi-compartment, network-based approaches for translational biomarker development.
- 20 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4580
Open AccessMulti-Compartment Transcriptomics Identifies a Persistent Inflammatory Program and a Network-Derived Diagnostic Signature in Polycythemia Vera
Polycythemia vera (PV) is a JAK2V617F-driven myeloproliferative neoplasm characterized by erythroid expansion, increased thrombotic risk, and heterogeneous clinical outcomes. Although prior studies have described key transcriptional abnormalities—including Janus kinase–signal transducer and activator of transcription (JAK–STAT) hyperactivation and chronic myeloinflammation—most have examined single hematopoietic compartments. A multi-compartment approach may reveal conserved and lineage-specific disease-associated transcriptional programs. Here, an integrated, multi-compartment transcriptomic analysis of publicly available microarray datasets was performed, spanning bone marrow (BM) CD34+ progenitors, peripheral blood (PB) CD34+ progenitors, and whole blood from PV patients and healthy controls, with independent validation in neutrophils. Differential gene expression, pathway enrichment, and protein–protein interaction network analyses were used to delineate conserved versus compartment-specific transcriptional programs and to evaluate persistence of progenitor-derived signatures into mature myeloid cells. Across compartments, PV demonstrated consistent enrichment of inflammatory, interferon, and JAK–STAT-associated pathways despite limited overlap at the individual gene level, indicating that core disease processes are maintained through lineage- and differentiation-stage-specific transcriptional reprogramming. Network analysis identified highly connected hub genes, which were used to derive a single-sample gene set enrichment (ssGSEA) signature. This signature showed strong diagnostic performance across cohorts; remained enriched in PV neutrophils; and correlated with platelet count, indolent disease status, and reduced levels in post-splenectomy patients. Together, these findings support a model in which PV is driven by stable, progenitor-derived inflammatory programs that persist across myeloid differentiation while incorporating compartment-specific adaptations, and highlight the value of multi-compartment, network-based approaches for translational biomarker development.
- Open Access
Liposome-Mediated Delivery of MERS Antigen Induces Potent Humoral and Cell-Mediated Immune Response in Mice
The advancements in the field of nanotechnology have provided a great platform for the development of effective antiviral vaccines. Liposome-mediated delivery of antigens has been shown to induce the antigen-specific stimulation of the humoral and cell-mediated immune responses. Here, we prepared dried, reconstituted vesicles (DRVs) from DPPC liposomes and used them as the vaccine carrier system for the Middle East respiratory syndrome coronavirus papain-like protease (DRVs-MERS-CoV PLpro). MERS-CoV PLpro emulsified in the Incomplete Freund’s Adjuvant (IFA-MERS-CoV PLpro) was used as a control. Immunization of mice with DRVs-MERS-CoV PLpro did not induce any notable toxicity, as revealed by the levels of the serum alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and lactate dehydrogenase (LDH) in the blood of immunized mice. Immunization with DRVs-MERS-CoV PLpro induced greater antigen-specific antibody titer and switching of IgG1 isotyping to IgG2a as compared to immunization with IFA-MERS-CoV PLpro. Moreover, splenocytes from mice immunized with DRVs-MERS-CoV PLpro exhibited greater proliferation in response to antigen stimulation. Moreover, splenocytes from DRVs-MERS-CoV PLpro-immunized mice secreted significantly higher IFN-γ as compared to splenocytes from IFA-MERS-CoV PLpro mice. In summary, DRVs-MERS-CoV PLpro may prove to be an effective prophylactic formulation to prevent MERS-CoV infection.
Open AccessLiposome-Mediated Delivery of MERS Antigen Induces Potent Humoral and Cell-Mediated Immune Response in Mice
The advancements in the field of nanotechnology have provided a great platform for the development of effective antiviral vaccines. Liposome-mediated delivery of antigens has been shown to induce the antigen-specific stimulation of the humoral and cell-mediated immune responses. Here, we prepared dried, reconstituted vesicles (DRVs) from DPPC liposomes and used them as the vaccine carrier system for the Middle East respiratory syndrome coronavirus papain-like protease (DRVs-MERS-CoV PLpro). MERS-CoV PLpro emulsified in the Incomplete Freund’s Adjuvant (IFA-MERS-CoV PLpro) was used as a control. Immunization of mice with DRVs-MERS-CoV PLpro did not induce any notable toxicity, as revealed by the levels of the serum alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and lactate dehydrogenase (LDH) in the blood of immunized mice. Immunization with DRVs-MERS-CoV PLpro induced greater antigen-specific antibody titer and switching of IgG1 isotyping to IgG2a as compared to immunization with IFA-MERS-CoV PLpro. Moreover, splenocytes from mice immunized with DRVs-MERS-CoV PLpro exhibited greater proliferation in response to antigen stimulation. Moreover, splenocytes from DRVs-MERS-CoV PLpro-immunized mice secreted significantly higher IFN-γ as compared to splenocytes from IFA-MERS-CoV PLpro mice. In summary, DRVs-MERS-CoV PLpro may prove to be an effective prophylactic formulation to prevent MERS-CoV infection.
- Open Access
- 1 August 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 140, 111726
Thyme oil alleviates Ova-induced bronchial asthma through modulating Th2 cytokines, IgE, TSLP and ROS
- 1 August 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 140, 111726
Open AccessThyme oil alleviates Ova-induced bronchial asthma through modulating Th2 cytokines, IgE, TSLP and ROS
- 1 August 2021
- Published by Elsevier in Journal of Molecular Liquids
- Vol. 335
Exploring the molecular interactions of Galantamine with human Transferrin: In-silico and in vitro insight
- 1 August 2021
- Published by Elsevier in Journal of Molecular Liquids
- Vol. 335
Exploring the molecular interactions of Galantamine with human Transferrin: In-silico and in vitro insight
- 1 January 2021
- Vol. 32 (2) , 51-56
Nigella sativa extract attenuates benzene induced oxidative DNA damage and abnormality in hematological parameters in rats
- 1 January 2021
- Vol. 32 (2) , 51-56
Nigella sativa extract attenuates benzene induced oxidative DNA damage and abnormality in hematological parameters in rats
- 24 September 2020
- Published by Taylor & Francis in Epigenomics
- Vol. 12 (20) , 1825-1843
Prognostic Value of the miRNA-27a and PPAR/RXRα Signaling Axis in Patients with Thyroid Carcinoma
The authors aimed to evaluate the prognostic value of miRNA-27a (miR-27a), peroxisome proliferator-activated receptor alpha/gamma (PPARα/γ) and retinoid X receptor alpha (RXRα) tissue expression in... Graphical abstract
- 24 September 2020
- Published by Taylor & Francis in Epigenomics
- Vol. 12 (20) , 1825-1843
Prognostic Value of the miRNA-27a and PPAR/RXRα Signaling Axis in Patients with Thyroid Carcinoma
The authors aimed to evaluate the prognostic value of miRNA-27a (miR-27a), peroxisome proliferator-activated receptor alpha/gamma (PPARα/γ) and retinoid X receptor alpha (RXRα) tissue expression in... Graphical abstract
- Open Access
- 1 August 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 5575-5589
Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells
Purpose: The overexpression of Her-2 in 25– 30% breast cancer cases and the crosstalk between Her-2 and fatty acid synthase (FASN) establishes Her-2 as a promising target for site-directed delivery. The present study aimed to develop the novel lipid base formulations to target and inhibit the cellular proliferation of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this goal, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated with the anti-Her-2 fab’ and encapsulated FASN siRNA against breast cancer cells. Methods: We evaluated the size, stability, cellular uptake and internalization of various formulations of liposomes. The antiproliferative gene silencing potential was investigated by the cell cytotoxicity, crystal violet, wound healing and Western blot analyses in Her-2+ and Her-2® breast cancer cells. Results: The data revealed that both nanosized FASN-siRNA-encapsulated liposomes showed significantly higher cellular uptake and internalization with enhanced stability. The cell viability of Her-2+ SK-BR3 cells treated with the targeted formulation of DSPC/Chol- and DOPE/CHEMS-encapsulating FASN-siRNA reduced to 30% and 20%, respectively, whereas it was found to be 45% and 36% in MCF-7 cells. The wounds were not only failed to close but they became broader in Her-2+ cells treated with targeted liposomes of siRNA. Consequently, the amount of FASN decreased by 80% in SK-BR3 cells treated with non-targeted liposomes and it was 30% and 60% in the MCF-7 cells treated with DSPC/Chol and DOPE/CHEMS liposomes, respectively. Conclusion: In this study, we developed the formulation that targeted Her-2 for the suppression of FASN and, therefore, inhibited the proliferation of breast cancer cells.
- 1 August 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 5575-5589
Open AccessFatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells
Purpose: The overexpression of Her-2 in 25– 30% breast cancer cases and the crosstalk between Her-2 and fatty acid synthase (FASN) establishes Her-2 as a promising target for site-directed delivery. The present study aimed to develop the novel lipid base formulations to target and inhibit the cellular proliferation of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this goal, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated with the anti-Her-2 fab’ and encapsulated FASN siRNA against breast cancer cells. Methods: We evaluated the size, stability, cellular uptake and internalization of various formulations of liposomes. The antiproliferative gene silencing potential was investigated by the cell cytotoxicity, crystal violet, wound healing and Western blot analyses in Her-2+ and Her-2® breast cancer cells. Results: The data revealed that both nanosized FASN-siRNA-encapsulated liposomes showed significantly higher cellular uptake and internalization with enhanced stability. The cell viability of Her-2+ SK-BR3 cells treated with the targeted formulation of DSPC/Chol- and DOPE/CHEMS-encapsulating FASN-siRNA reduced to 30% and 20%, respectively, whereas it was found to be 45% and 36% in MCF-7 cells. The wounds were not only failed to close but they became broader in Her-2+ cells treated with targeted liposomes of siRNA. Consequently, the amount of FASN decreased by 80% in SK-BR3 cells treated with non-targeted liposomes and it was 30% and 60% in the MCF-7 cells treated with DSPC/Chol and DOPE/CHEMS liposomes, respectively. Conclusion: In this study, we developed the formulation that targeted Her-2 for the suppression of FASN and, therefore, inhibited the proliferation of breast cancer cells.
- Open Access
- 15 June 2020
- Published by Springer Nature in British Journal of Cancer
- Vol. 123 (5) , 742-751
Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia
Background: While current chemotherapy has increased cure rates for children with acute lymphoblastic leukaemia (ALL), the largest number of relapsing patients are still stratified as medium risk (MR) at diagnosis (50–60%). This highlights an opportunity to develop improved relapse-prediction models for MR patients. We hypothesised that bone marrow from MR patients who eventually relapsed would regrow faster in a patient-derived xenograft (PDX) model after induction chemotherapy than samples from patients in long-term remission. Methods: Diagnostic bone marrow aspirates from 30 paediatric MR-ALL patients (19 who relapsed, 11 who experienced remission) were inoculated into immune-deficient (NSG) mice and subsequently treated with either control or an induction-type regimen of vincristine, dexamethasone, and L-asparaginase (VXL). Engraftment was monitored by enumeration of the proportion of human CD45+ cells (%huCD45+) in the murine peripheral blood, and events were defined a priori as the time to reach 1% huCD45+, 25% huCD45+ (TT25%) or clinical manifestations of leukaemia (TTL). Results: The TT25% value significantly predicted MR patient relapse. Mutational profiles of PDXs matched their tumours of origin, with a clonal shift towards relapse observed in one set of VXL-treated PDXs. Conclusions: In conclusion, establishing PDXs at diagnosis and subsequently applying chemotherapy has the potential to improve relapse prediction in paediatric MR-ALL.
- 15 June 2020
- Published by Springer Nature in British Journal of Cancer
- Vol. 123 (5) , 742-751
Open AccessExamining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia
Background: While current chemotherapy has increased cure rates for children with acute lymphoblastic leukaemia (ALL), the largest number of relapsing patients are still stratified as medium risk (MR) at diagnosis (50–60%). This highlights an opportunity to develop improved relapse-prediction models for MR patients. We hypothesised that bone marrow from MR patients who eventually relapsed would regrow faster in a patient-derived xenograft (PDX) model after induction chemotherapy than samples from patients in long-term remission. Methods: Diagnostic bone marrow aspirates from 30 paediatric MR-ALL patients (19 who relapsed, 11 who experienced remission) were inoculated into immune-deficient (NSG) mice and subsequently treated with either control or an induction-type regimen of vincristine, dexamethasone, and L-asparaginase (VXL). Engraftment was monitored by enumeration of the proportion of human CD45+ cells (%huCD45+) in the murine peripheral blood, and events were defined a priori as the time to reach 1% huCD45+, 25% huCD45+ (TT25%) or clinical manifestations of leukaemia (TTL). Results: The TT25% value significantly predicted MR patient relapse. Mutational profiles of PDXs matched their tumours of origin, with a clonal shift towards relapse observed in one set of VXL-treated PDXs. Conclusions: In conclusion, establishing PDXs at diagnosis and subsequently applying chemotherapy has the potential to improve relapse prediction in paediatric MR-ALL.
- Open Access
- 1 May 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 3681-3693
Potential of Methylglyoxal-Conjugated Chitosan Nanoparticles in Treatment of Fluconazole-Resistant Candida albicans Infection in a Murine Model
Background: Fungal infections are becoming more prevalent and threatening because of the continuous emergence of azole-resistant fungal infections. The present study was aimed to assess the activity of free Methylglyoxal (MG) or MG-conjugated chitosan nanoparticles (MGCN) against fluconazole-resistant Candida albicans. Materials and Methods: A novel formulation of MGCN was prepared and characterized to determine their size, shape and polydispersity index. Moreover, the efficacy of fluconazole or MG or MGCN was determined against intracellular C. albicans in macrophages and the systematic candidiasis in a murine model. The safety of MG or MGCN was tested in mice by analyzing the levels of hepatic and renal toxicity parameters. Results: Candida albicans did not respond to fluconazole, even at the highest dose of 20 mg/kg, whereas MG and MGCN effectively eliminated C. albicans from the macrophages and infected mice. Mice in the group treated with MGCN at a dose of 10 mg/kg exhibited a 90% survival rate and showed the lowest fungal load in the kidney, whereas the mice treated with free MG at the same dose exhibited 50% survival rate. Moreover, the administration of MG or MGCN did not induce any liver and kidney toxicity in the treated mice. Conclusion: The findings of the present work suggest that MGCN may be proved a promising therapeutic formulation to treat azole-resistant C. albicans infections.
- 1 May 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 3681-3693
Open AccessPotential of Methylglyoxal-Conjugated Chitosan Nanoparticles in Treatment of Fluconazole-Resistant Candida albicans Infection in a Murine Model
Background: Fungal infections are becoming more prevalent and threatening because of the continuous emergence of azole-resistant fungal infections. The present study was aimed to assess the activity of free Methylglyoxal (MG) or MG-conjugated chitosan nanoparticles (MGCN) against fluconazole-resistant Candida albicans. Materials and Methods: A novel formulation of MGCN was prepared and characterized to determine their size, shape and polydispersity index. Moreover, the efficacy of fluconazole or MG or MGCN was determined against intracellular C. albicans in macrophages and the systematic candidiasis in a murine model. The safety of MG or MGCN was tested in mice by analyzing the levels of hepatic and renal toxicity parameters. Results: Candida albicans did not respond to fluconazole, even at the highest dose of 20 mg/kg, whereas MG and MGCN effectively eliminated C. albicans from the macrophages and infected mice. Mice in the group treated with MGCN at a dose of 10 mg/kg exhibited a 90% survival rate and showed the lowest fungal load in the kidney, whereas the mice treated with free MG at the same dose exhibited 50% survival rate. Moreover, the administration of MG or MGCN did not induce any liver and kidney toxicity in the treated mice. Conclusion: The findings of the present work suggest that MGCN may be proved a promising therapeutic formulation to treat azole-resistant C. albicans infections.